Definium Therapeutics Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Definium Therapeutics s intäkter har minskat med en genomsnittlig årlig takt på -21.4%, medan Pharmaceuticals -branschen såg intäkter på växer vid 9.4% årligen.
Viktig information
-21.38%
Tillväxttakt i vinsten
11.96%
Tillväxttakt för EPS
| Pharmaceuticals Tillväxt i branschen | 5.95% |
| Intäkternas tillväxttakt | n/a |
| Avkastning på eget kapital | -85.19% |
| Nettomarginal | n/a |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Seeking Alpha • Apr 17
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Summary Definium Therapeutics, Inc. is maintained at a Strong Buy due to imminent 2026 catalysts and robust late-stage pipeline progress. DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation. With $411.6M cash and no near-term funding needs, DFTX is well-positioned to execute through multiple clinical milestones into 2028. Read the full article on Seeking Alpha
Ny berättelse • Apr 02
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 19
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 04
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 21
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Psychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaSeeking Alpha • Apr 04
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaSeeking Alpha • Feb 02
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Summary Primary endpoint met of HAM-A scores at week 4 met in phase 2b MMED008 study, when Generalized Anxiety Disorder patients were given MM-120. 12-week HAM-A results from phase 2b MMED008 study in GAD to be released end of Q1 of 2024 with full data set at upcoming medical meeting in 2024. End of phase 2 meeting with FDA to discuss advancement of MM-120 for GAD expected in the 1st half of 2024; Phase 3 trial initiation expected 2nd half of 2024. The generalized anxiety disorder market size is estimated to reach $8.1 billion by 2027. Read the full article on Seeking AlphaAnalysartikel • May 23
Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Definium Therapeutics tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -238 | 58 | 136 |
| 31 Dec 25 | 0 | -184 | 49 | 118 |
| 30 Sep 25 | 0 | -168 | 45 | 106 |
| 30 Jun 25 | 0 | -115 | 38 | 92 |
| 31 Mar 25 | 0 | -78 | 37 | 77 |
| 31 Dec 24 | 0 | -109 | 39 | 65 |
| 30 Sep 24 | 0 | -98 | 39 | 55 |
| 30 Jun 24 | 0 | -102 | 39 | 51 |
| 31 Mar 24 | 0 | -125 | 44 | 51 |
| 31 Dec 23 | 0 | -96 | 42 | 52 |
| 30 Sep 23 | 0 | -77 | 36 | 49 |
| 30 Jun 23 | 0 | -75 | 37 | 44 |
| 31 Mar 23 | 0 | -63 | 30 | 39 |
| 31 Dec 22 | 0 | -57 | 30 | 36 |
| 30 Sep 22 | 0 | -69 | 32 | 38 |
| 30 Jun 22 | 0 | -69 | 31 | 39 |
| 31 Mar 22 | 0 | -98 | 60 | 38 |
| 31 Dec 21 | 0 | -93 | 59 | 35 |
| 30 Sep 21 | 0 | -89 | 59 | 32 |
| 30 Jun 21 | 0 | -80 | 53 | 29 |
| 31 Mar 21 | 0 | -41 | 19 | 24 |
| 31 Dec 20 | 0 | -34 | 14 | 19 |
| 30 Sep 20 | 0 | -29 | 11 | 14 |
Kvalitetsintäkter: DFTX är för närvarande olönsam.
Växande vinstmarginal: DFTX är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: DFTX är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 21.4% per år.
Accelererande tillväxt: Det går inte att jämföra DFTX s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: DFTX är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Pharmaceuticals branschen ( -4.8% ).
Avkastning på eget kapital
Hög ROE: DFTX har en negativ avkastning på eget kapital ( -85.19% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/22 09:46 |
| Aktiekurs vid dagens slut | 2026/06/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Definium Therapeutics, Inc. bevakas av 22 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Christopher Chen | Baird |